Boston Scientific has disclosed that it has purchased privately-held nVision Medical Corporation at a price of $275 million. The focus area of nVision is women’s health and it has developed a device which is used to collect cells present in fallopian tubes in order to diagnose ovarian cancer. According to various studies a couple of ovarian cancers start in the fallopian tubes.
“I started nVision with a goal of creating a tool to address an unmet need in women’s health. I am proud of our achievements in advancing efforts to help with the early detection of ovarian cancer,” the chief executive officer and founder of nVision, Surbhi Sarna, said.
Among women ovarian cancer is the No. 5 leading cause of cancer-associated deaths. In the United States over two million women face a high risk of developing ovarian cancer. Women who have a family history of the disease or those with BRCA1 BRCA2 gene mutations are at an especially high risk. Making matters worse is the fact that women suffering from ovarian cancer are asymptomatic till the disease has progressed to the late stages.
So far there haven’t been any early screening tests that are recommended. Neither has an effective way of conducting a biopsy of the fallopian tube cells. This has seen about 300,000 women choose to have their fallopian tubes and ovaries removed every year in order to reduce the ovarian cancer risk.
According to the president of Boston Scientific’s MedSurg, Dave Pierce, the market for the nVision device could grow to a figure of $500 million in the near-term and $2 billion in the medium-term. From preliminary clinical research the device developed by nVision has proven to be effective at collecting cells from fallopian tubes and after tests the cells correlate with the ovarian cancer diagnosis post-surgery.
Additional clinical research on the nVision device will be conducted by Boston Scientific in order to determine how cells collected from fallopian tubes can be used in rendering a diagnosis before surgery in order to assist women who are at high risk of developing ovarian cancer make a decision. In stage three of ovarian cancer the survival rate is around 30% while in stage four the survival rate is around 17%. Preventive action is thus urged by physicians due to the low survival rates. However while removing fallopian tubes and ovaries reduces the ovarian cancer risk, it also raises the risk of developing cardiovascular issues and cognitive impairment.